World Health Organization Raises Warning Over Critical Scarcity of Weight-Loss Medications
Under a tenth of individuals that would benefit from weight-loss injections including Wegovy have access to them, caution the global health agency as it releases its first guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to this class of drugs.
Based on forecasts, over two billion could be obese by 2030 without intervention.
"The latest guidelines affirms that excess weight is a long-term condition that can be managed with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major hurdles to universal access to the treatments that can aid individuals in losing considerable weight, notes the agency.
GLP-1 Therapy Shortage
Despite the current most optimistic case, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of those who need them, per the WHO.
The advice urges governments and firms to expand access, through measures like patent sharing.
A patent on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Drugs Work
These medications imitate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals eat less.
Patients typically begin shedding pounds after several weeks of starting on the once-weekly jabs.
Studies indicates users may regain a significant portion within a year of stopping the drug, when their normal food cravings resume.
To be above a healthy weight increases your likelihood for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns people in all nations and was associated with millions of deaths worldwide in 2024, as per the WHO.
